Uppsala, Sweden – December 28, 2012 - The number of shares and votes in Orexo
has changed as a result of the exercise of warrants.
Today, the last trading day of the month, there are in total 29,946,332 shares
and votes in the company.
For further information, please contact:
Carl-Johan Blomberg, CFO
Tel: +46-706 33 67 11, Email: email@example.com
Orexo AB is an emerging specialty pharma company developing improved treatments
using proprietary drug delivery technology. Orexo’s expertise is within the area
of reformulation technologies and especially sublingual formulations. The
company has a portfolio of revenue generating EU and US approved products
currently marketed under licence and a pipeline of several reformulations of
approved compounds for areas of unmet medical need. Orexo also has collaboration
projects with several international pharma companies. Orexo AB is headquartered
in Sweden has 100 employees and is listed on NASDAQ-OMX. The largest
shareholders are Novo A/S and HealthCap.
For information about Orexo please visit www.orexo.com
Orexo is required under the Financial Instruments Trading Act to make the
information in this press release public. The information was submitted for
publication at 4:00 pm CET on December 28, 2012.
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
2321 Rosecrans Avenue.
El Segundo, CA 90245 Phone: (800) 307-6627 Fax: (800) 307-3567
25 Basinghall Street,
London EC2V 5HA
UK Phone: +1 866-465-8454